AVXL ANAVEX LIFE SCIENCES CORP revenue, earnings and financials
For the quarter ended June 30, 2026, ANAVEX LIFE SCIENCES CORP reported revenue of n/a, net income of $7.82M and diluted EPS of $0.08; for the fiscal year ended September 2025 revenue was n/a.
AVXL annual revenue and earnings
- Fiscal year ended Sep 2025: revenue n/a, gross profit n/a, operating income −$51.4M, net income −$46.4M (margin n/a), EPS −$0.54
- Fiscal year ended Sep 2024: revenue n/a, gross profit n/a, operating income −$52.9M, net income −$43.0M (margin n/a), EPS −$0.52
- Fiscal year ended Sep 2023: revenue n/a, gross profit n/a, operating income −$55.8M, net income −$47.5M (margin n/a), EPS −$0.60
- Fiscal year ended Sep 2022: revenue n/a, gross profit n/a, operating income −$51.0M, net income −$48.0M (margin n/a), EPS −$0.62
- Fiscal year ended Sep 2021: revenue n/a, gross profit n/a, operating income −$42.0M, net income −$37.9M (margin n/a), EPS −$0.54
AVXL quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income $7.82M, EPS $0.08
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.34M, EPS −$0.06
- Quarter ended Dec 31, 2025: revenue n/a, net income −$5.68M, EPS −$0.06
- Quarter ended Sep 30, 2025 (from the annual report): revenue n/a, net income −$9.83M, EPS −$0.11
- Quarter ended Jun 30, 2025: revenue n/a, net income −$13.2M, EPS −$0.16
- Quarter ended Mar 31, 2025: revenue n/a, net income −$11.2M, EPS −$0.13
- Quarter ended Dec 31, 2024: revenue n/a, net income −$12.1M, EPS −$0.14
- Quarter ended Sep 30, 2024 (from the annual report): revenue n/a, net income −$11.6M, EPS −$0.14
- Quarter ended Jun 30, 2024: revenue n/a, net income −$12.2M, EPS −$0.14
- Quarter ended Mar 31, 2024: revenue n/a, net income −$10.5M, EPS −$0.13
- Quarter ended Dec 31, 2023: revenue n/a, net income −$8.62M, EPS −$0.11
- Quarter ended Sep 30, 2023 (from the annual report): revenue n/a, net income −$10.1M, EPS −$0.12
- Quarter ended Jun 30, 2023: revenue n/a, net income −$11.3M, EPS −$0.14
- Quarter ended Mar 31, 2023: revenue n/a, net income −$13.1M, EPS −$0.17
- Quarter ended Dec 31, 2022: revenue n/a, net income −$13.0M, EPS −$0.17
- Quarter ended Sep 30, 2022 (from the annual report): revenue n/a, net income −$14.3M, EPS n/a
- Quarter ended Jun 30, 2022: revenue n/a, net income −$12.4M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$10.4M, EPS n/a
- Quarter ended Dec 31, 2021: revenue n/a, net income −$10.9M, EPS −$0.14
- Quarter ended Jun 30, 2021: revenue n/a, net income −$10.2M, EPS −$0.14
AVXL cash flow, buybacks and dividends
- Fiscal year ended Sep 2025: operating cash flow −$39.0M, share buybacks n/a
- Fiscal year ended Sep 2024: operating cash flow −$30.8M, share buybacks n/a
- Fiscal year ended Sep 2023: operating cash flow −$27.8M, share buybacks n/a
- Fiscal year ended Sep 2022: operating cash flow −$24.2M, share buybacks n/a
- Fiscal year ended Sep 2021: operating cash flow −$30.4M, share buybacks n/a
AVXL balance sheet
- Jun 30, 2026: cash $118M, total assets $120M, total liabilities $7.69M, shareholders' equity $112M
- Mar 31, 2026: cash $127M, total assets $129M, total liabilities $7.06M, shareholders' equity $122M
- Dec 31, 2025: cash $132M, total assets $133M, total liabilities $6.37M, shareholders' equity $127M
- Sep 30, 2025: cash $103M, total assets $104M, total liabilities $8.95M, shareholders' equity $94.9M
- Jun 30, 2025: cash $101M, total assets $102M, total liabilities $11.5M, shareholders' equity $91.0M
- Mar 31, 2025: cash $116M, total assets $117M, total liabilities $17.4M, shareholders' equity $99.8M
- Dec 31, 2024: cash $121M, total assets $124M, total liabilities $13.1M, shareholders' equity $111M
- Sep 30, 2024: cash $132M, total assets $136M, total liabilities $15.3M, shareholders' equity $120M
Is AVXL profitable?
No. ANAVEX LIFE SCIENCES CORP lost $13.0M over the last four quarters.
What is AVXL's EPS?
Diluted earnings per share over the last four quarters were −$0.15; $0.08 in the latest quarter.